Search for Stocks /

šŸ”„ Emcure Pharmaceuticals Q4 FY25 Results: ā‚¹707 Cr PAT, ā‚¹7,896 Cr Revenue, EPS ā‚¹36.43 ā€” Time to Inject This Stock into Your Portfolio?

by Prashant Marathe | EduInvesting.in | 23 May 2025

šŸ“Œ At a Glance:

MetricQ4 FY25FY25 Total
šŸ§¾ Revenue from Opsā‚¹2,116 Crā‚¹7,896 Cr
šŸ’° Net Profit (PAT)ā‚¹197 Crā‚¹707 Cr
šŸ“ˆ EPS (Annualized)ā‚¹9.97ā‚¹36.43
šŸŽÆ CMPā‚¹1,189 (+10% today)

šŸ‘‰ With margins rising, a distribution tie-up with Sanofi, global acquisitions, and a listing only 10 months old, Emcure is now flexing serious post-IPO muscle.

šŸ§¬ About Emcure Pharmaceuticals

  • Based in Pune, founded 1981
  • Present in 70+ countries
  • Top 12 pharma player in India
  • Strong franchises: Womenā€™s Health, Cardio, OTC, and now expanding in Dermatology
  • Acquired Mantra Pharma (Canada) and partnered with Sanofi for Cardiovascular product distribution in India

šŸ“Š Financial Snapshot ā€“ FY25 (Consolidated)

MetricFY25FY24YoY Growth
Revenue from Opsā‚¹7,896 Crā‚¹6,658 Cr+18.6%
EBITDAā‚¹1,469 Crā‚¹1,230 Cr+19.4%
Net Profitā‚¹707 Crā‚¹528 Cr+34.1%
EPSā‚¹36.43ā‚¹27.54
To Read Full 16 Point
Join 10,000+ investors who read this every week.
Become a member
To Read Full 16 Point

Leave a Reply